Traditional medical curricula generally place the majority of foundational science learning into the pre-clerkship years. Yet, it has been recognized that foundational science education should occur across the medical curriculum to promote excellence in clinical performance. This session will provide participants with an innovative approach to integrating foundational sciences and meaningful clinical experiences in the post-clerkship curriculum. Participants will learn about several educational strategies and the resources necessary to achieve successful integration of foundational sciences and patient care. Furthermore, participants will recognize the challenges and learn practical solutions of this approach in order to implement post-clerkship foundational science integration at their own institutions.
Presenter Bios
Kimberly B. Dahlman, PhD
Kimberly Dahlman, PhDis an Assistant Professor of Medicine,Curriculum Leader of the Integrated Science Courses(ISCs),and Director of the Innovative Translational Research Shared Resource(ITR) at Vanderbilt University Medical Center. Dr. Dahlman earned her PhD in Cancer Biology at Vanderbilt University and completed her postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center. She has demonstrated leadership in education for medical students, biomedical science PhD trainees, postdoctoral fellows, practicing oncologists, and core facility directors. She currently oversees the development and execution of 16 ISCs and co-directs the “Clinical Cancer Medicine” ISC. She has been recognized for her excellent contributions to education at the Vanderbilt University School of Medicine (VUSM) by election to the Academy for Excellence in Education and a Member-at-Large position on the Academy Board. Recently, she was awarded the distinction of Master Science Teacher from VUSM. Dr. Dahlman is also President of the Southeastern Association of Shared Resources where she oversees the educational programming and execution of a regional professional development meeting for shared resource directors, managers, administrators, and staff.In addition to her educational pursuits, Dr. Dahlman directs a cancer research laboratory with a focus on determining how genomic alterations modulate tumor growth and the response to standard-of-care and investigational therapies. The overall goal of her scientific research is to uncover novel cancer therapeutic targets and biomarkers. As ITR Director,she designs and manages correlative study workflow, quality assurance, and quality control for cancer clinical trials